Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen - 08/09/11
Abstract |
Background: The use of adequate adjuvants to modulate the allergic TH2-type immune response is a promising concept for future immunotherapy of type I allergy. Bacterial DNA or oligodeoxynucleotides containing CpG motifs (CpG-ODNs) have been demonstrated to foster TH1-type immune responses. Objective: We investigated the adjuvanticity of CpG-ODNs and their capability to modulate the allergic TH2 response in a mouse model. Methods: BALB/c mice were treated with CpG-ODNs and Bet v 1, the major birch pollen allergen, in different experimental setups. Allergen-specific antibody responses, TH cytokines, and eosinophilic infiltration of the airways were investigated. Results: Intraperitoneal administration of Bet v 1 together with aluminium hydroxide led to a typical TH2 response. In contrast, coadminstration of CpG-ODNs with Bet v 1 in aluminium hydroxide resulted in markedly increased TH1 activities (high IgG2a levels) and subsequently to reduced airway inflammation. The TH1-like immune response indicated by these humoral findings was also reflected by decreased IL-5 and increased IFN-γ levels in cell cultures. CpG-ODNs as sole adjuvants with Bet v 1 did not lead to measureable Ig responses after subcutaneous or intraperitoneal immunizations; after intranasal application, 3 of 10 mice reacted. Nevertheless, a prophylactic effect was obtained with all routes tested; that is, mice treated subsequently with an established aerosol sensitization protocol displayed altered immune responses characterized by drastically elevated levels of Bet v 1–specific IgG2a, indicating a TH1/TH0-like immunity. Application of CpG-ODNs after aerosol sensitization also induced IgG2a. Conclusion: By inducing TH1/TH0-biased immune responses to allergens, the use of CpG-ODNs as adjuvants may have important impacts for new forms of specific immunotherapy in type I hypersensitivity. (J Allergy Clin Immunol 1999;1015-23.)
Le texte complet de cet article est disponible en PDF.Keywords : CpG oligodeoxynucleotides, immunomodulation, type I allergy, TH1/TH2, Bet v 1, BALB/c mice
Abbreviations : AS, BAL, CpG-ODN, ISS, SIT
Plan
| Supported by grants from the Austrian Science Foundation (P12889-MED and S7206-MOB), the Austrian Federal Ministry of Science and Transportation, and ALK-Abello, Hørsholm, Denmark. |
|
| Reprint requests: Christof Ebner, MD, Institut für Allgemeine und Experimentelle Pathologie, Universität Wien, AKH-EBO 3Q, Währinger Gürtel 18-20, A-1090 Wien, Austria. |
|
| 0091-6749/99 $8.00 + 0 1/1/101793 |
Vol 104 - N° 5
P. 1015-1023 - novembre 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
